Enzolytics Inc. Supports Sagaliam Acquisition Corp Response to Competitors False and Misleading Press Release
Enzolytics Inc. Supports Sagaliam Acquisition Corp Response to Competitors False and Misleading Press Release
ALLEN, TX / ACCESSWIRE / July 26, 2024 / Enzolytics, Inc. (OTC PINK:ENZC) (enzolytics.com) (the "Company") stated today that the Company will whole heartedly support any and all efforts by Sagaliam Acquisition Corp ("SAGA") in its campaign to stop another attempt by NIKA Pharmaceutical and its CEO, Dimtar Savov, falsely claiming rights to patents issued to Harry H. Zhabilov and the Zhabilov Trust for the Immunotherapy treatment of HIV/AIDS. Mr. Savov has, since defaulting on licensing agreements and losses in civil court actions in the US and Bulgarian court systems, erroneously and maliciously asserted claims to ITV-1 in his attempt to mislead the investing public and to harm the shareholder value of SAGA as well as the Company. The exclusive license holder of this intellectual property is Virogentics, Inc., a wholly owned subsidiary of Sagaliam.
ALLEN, TX / ACCESSWIRE / 2024年7月26日 / Enzolytics,Inc.(OTC PINK:ENZC)(enzolytics.com)(“公司”)今天表示,公司将全力支持Sagaliam Acquisition Corp(“SAGA”)在其阻止NIKA制药及其首席执行官Dimtar Savov假称享有针对Harry H. Zhabilov和Zhabilov信托基金发行的HIV/AIDS免疫疗法专利权的另一次尝试的所有努力。自从Savov在授权协议上拖欠并在美国和保加利亚法院的民事诉讼中亏损以来,他错误并恶意地宣称对ITV-1的主张,试图误导投资公众并损害SAGA以及公司的股东价值。这项知识产权的独家许可证持有人是Sagaliam的全资子公司Virogentics,Inc。Steve Sharabura,Enzolytics临时首席执行官,评论道:“我和董事会坚定地与Sagaliam保持一致,终结这场悲剧并保护两个实体的股东价值。”关于Enzolytics,Inc. Enzolytics,Inc.正在过渡,从一家致力于推广其专有蛋白质和单克隆抗体以治疗令人严重困扰的传染病的药物开发公司,转变为致力于医疗设备、医疗测试和营养保健产品的销售、营销和分销实体。 Enzolytics,Inc. Steve Sharabura,首席执行官 X / Twitter:@EnzolyticsInc
Sagaliam press release issued on July 25, 2017:
Sagaliam 于 2017年7月25日发布的新闻稿:
Steve Sharabura, Interim CEO of Enzolytics, commented, "I and the Board of Directors are steadfastly aligned with Sagaliam to bring to an end this travesty and the protection of both entities' shareholder value."
Steve Sharabura,Enzolytics临时首席执行官,评论道:“我和董事会坚定地与Sagaliam保持一致,终结这场悲剧并保护两个实体的股东价值。”
About Enzolytics, Inc.
关于Enzolytics,Inc。 Enzolytics,Inc.正在过渡,从一家致力于推广其专有蛋白质和单克隆抗体以治疗令人严重困扰的传染病的药物开发公司,转变为致力于医疗设备、医疗测试和营养保健产品的销售、营销和分销实体。
Enzolytics, Inc. is transitioning from a drug development company committed to commercializing its proprietary proteins and monoclonal antibodies to treat debilitating infectious diseases to a sales, marketing and distribution entity focusing on medical devices, medical testing and nutraceutical products.
关于Enzolytics,Inc。 Enzolytics,Inc.正在过渡,从一家致力于推广其专有蛋白质和单克隆抗体以治疗令人严重困扰的传染病的药物开发公司,转变为致力于医疗设备、医疗测试和营养保健产品的销售、营销和分销实体。 Enzolytics,Inc。 Steve Sharabura,首席执行官 X / Twitter:@EnzolyticsInc
Forward Looking Statements
前瞻性声明
The disclosure herein includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "would," "plan," "predict," "potential," "seem," "seek," "future," "outlook," and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding projections, estimates and forecasts of revenue and other financial and performance metrics and projections of market opportunity and expectations, Company's ability to enter into a definitive business combination agreement and Company's ability to obtain the financing necessary to consummate the potential business combination transaction. These statements are based on various assumptions and on the current expectations of Company's management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Company. These forward-looking statements are subject to a number of risks and uncertainties, including: Company's ability to enter into a definitive agreement with respect to the proposed business combination or consummate a transaction; the risk that the approval of the stockholders of Company for the potential transaction is not obtained; failure to realize the anticipated benefits of the potential transaction, including as a result of a delay in consummating the potential transaction or difficulty in integrating the businesses of Company; the amount of redemption requests made by Company's stockholders and the amount of funds remaining in Company's trust account after satisfaction of such requests; those factors discussed in Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023 under the heading "Risk Factors," and other documents of Company filed, or to be filed, with the SEC. If the risks materialize or assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Company presently does not know or that Company currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Company's expectations, plans or forecasts of future events and views as of the date hereof. Company anticipates that subsequent events and developments will cause Company's assessments to change. However, while Company may elect to update these forward-looking statements at some point in the future, Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Company's assessments as of any date subsequent to the date of this disclosure statement. Accordingly, undue reliance should not be placed upon the forward-looking statements.
本披露中包括某些声明,这些声明不是历史事实,但是是根据1995年美国私人证券诉讼改革法案下的安全港规定的前瞻性声明。通常,前瞻性声明伴随着“相信”、“可能”、“将”、“估计”、“继续”、“预期”、“应该”、“愿望”、“计划”、“预测”、“潜力”、“看起来”、“寻求”、“未来”、“展望”和类似表达趋势的词语,或者预测或指示未来事件或趋势的表达,或者不是历史事实的声明。这些前瞻性声明仅用于说明目的,并且并不旨在作为任何投资者的保证、保障、预测或确切的事实或概率声明,任何投资者不得依赖这些声明。实际事件和情况很难或不可能预测,并且将有所不同。许多实际事件和情况超出了公司的控制范围。这些前瞻性声明还受到许多风险和不确定性的影响,包括:公司能否进入有关潜在交易的确定性协议或完成交易;公司的股东能否获得有关所有潜在交易的批准;由于将潜在交易达成协议或整合公司的业务而未能实现预期的收益;公司股东提出的赎回请求的数量以及满足此类请求后公司信托账户内剩余的资金数量;公司提交给SEC的10-K年度报告中讨论的因素,以及公司已提交或将提交给SEC的其他文件。如果这些风险成为现实或假设被证明不正确,则实际结果可能会与这些前瞻性声明所暗示的结果有所不同。还可能存在公司目前不知道或公司目前认为不重要的其他风险,可能导致实际结果与前瞻性声明中所包含的结果有所不同。另外,前瞻性声明反映公司管理层对未来事件和展望的期望、计划或预测,以及自本日以来的观点。公司预计后续事件和发展将导致公司的评估发生变化。然而,虽然公司可能在未来某个时间选择更新这些前瞻性声明,但公司明确声明没有任何义务这样做。因此,不得将这些前瞻性声明作为代表公司评估的任何日期之后的任何日期。因此,不应过度依赖前瞻性声明。
CONTACT INFORMATION
联系信息
Enzolytics, Inc.
Steve Sharabura, Chief Executive Officer
3002 Royal Palm
Baytown, Texas 77523
Tel: (845) 925-4597
X/Twitter: @EnzolyticsInc
Enzolytics,Inc。
Steve Sharabura,首席执行官
3002 Royal Palm
Baytown, Texas 77523
电话:(845) 925-4597
X / Twitter:@EnzolyticsInc
SOURCE: Enzolytics, Inc.
来源:Enzolytics,Inc。